A randomized trial found that intensive screening for peritoneal metastases in advanced colon cancer led to more cases being detected and treated, but did not improve 5-year overall or disease-free survival compared to standard care .
The COLOPEC trial addressed a practical question in colorectal cancer management: does catching peritoneal metastases early, combined with aggressive treatment via hyperthermic intraperitoneal chemotherapy (HIPEC), improve long-term outcomes in patients with locally advanced colon cancer?
Researchers followed 202 patients from the COLOPEC trial who had undergone curative surgery for stage T4 or perforated colon cancer. These patients received either adjuvant HIPEC or standard chemotherapy, plus a mandatory diagnostic laparoscopy at 18 months to screen for peritoneal spread. They compared these outcomes to 202 matched control patients from routine practice in Dutch hospitals during 2014-2015, who received standard care without the intensive screening protocol.
The results revealed a detection paradox. Patients in the COLOPEC trial had nearly three times the rate of peritoneal metastases diagnosed at 5 years (24.4% versus 9.5%), and were significantly more likely to undergo cytoreductive surgery with HIPEC for peritoneal recurrence (13.9% versus 3.5%). However, these differences in detection and treatment intensity did not translate into survival benefits. Five-year overall survival was 70.2% in the trial group and 72.8% in the control group (not statistically significant). Disease-free survival followed the same pattern: 62.1% versus 65.2% respectively, again showing no significant difference.
This unexpected finding suggests that either the peritoneal metastases detected through intensive screening were not clinically significant in many cases, or that the HIPEC intervention itself provided no survival advantage despite treating more patients. The study essentially demonstrates that more aggressive surveillance and treatment of detected peritoneal disease did not improve the likelihood of long-term survival, raising important questions about the clinical utility of this approach in routine practice.
For patients with advanced colon cancer: This research suggests that intensive screening protocols for peritoneal spread may not warrant the additional procedures, costs, and potential morbidity if the goal is survival benefit. Standard surveillance and chemotherapy appear to produce comparable long-term outcomes. The findings support a measured approach to cancer care rather than increasingly aggressive detection strategies.
For cancer care discussions: If you or a loved one faces treatment decisions for locally advanced colon cancer, these results provide evidence that standard care pathways are not inferior to more intensive surveillance approaches. It's worth asking your oncology team whether additional screening procedures are likely to change your treatment plan or improve survival, since this study suggests they may not.
For cancer research: The study highlights the importance of comparing new screening strategies directly to standard care rather than assuming that earlier detection automatically leads to better outcomes. It's a reminder that more treatment is not always better treatment, even when detection rates improve substantially.
| Characteristic | Details |
|---|---|
| Study Type | Randomized controlled trial with matched retrospective control cohort |
| Sample Size | 202 trial patients + 202 matched control patients |
| Intervention | Adjuvant HIPEC or standard chemotherapy plus mandatory diagnostic laparoscopy at 18 months |
| Control | Standard colon cancer care without intensive screening protocol |
| Primary Outcome | 5-year overall survival, disease-free survival, peritoneal metastases incidence |
| Results | No significant difference in overall or disease-free survival despite higher detection and treatment of peritoneal metastases in trial group |
| Journal | Colorectal Disease |
| PubMed ID | 42755020 |
| Evidence Tier | A tier (RCT with real-world comparison) |
Verwaal VD, et al. Detection and treatment of peritoneal metastases in colon cancer: COLOPEC trial compared to routine practice. Colorectal Disease. PubMed: 42755020
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.